Recently, the 5th Asian Cell and Gene Therapy Innovation Summit of CGT Asia 2024 and the 2nd 3D Cell Culture and Organoid R&D Summit of 3DCC were held in Shanghai. This event serves as the premier CGT industry conference in the Asia Pacific region, organized by Taas labs with support from the Shanghai Biomedical Industry Promotion Center and the Skin and Soft Tissue Repair and Reconstruction Technology Branch of the China Medical Biotechnology Association (TCMRR). Simultaneously, at this conference, the "CGT Awards" - a ceremony honoring outstanding achievements in the Asia Pacific Cell and Gene Therapy industry - was also conducted.

The "CGT Awards Asia Pacific Cell and Gene Therapy Industry Star" award is an industry segmentation track selection initiated by Taas labs, aiming to provide strong support for the transformation direction of cell and gene therapy scientific research, promote the improvement of industry research and development strength, and enhance brand influence. The selection went through the primary election of more than 500,000 professionals, the review stage from the technical utility and innovation, market performance (market share), customer evaluation (quality assurance, service process clarity), development space and other dimensions of the comprehensive assessment, and the expert jury nominated and voted for the final 38 winners. Dr. David Du, CEO of Evergreen Therapeutics, as a member of the expert jury and the first presenter of the award, presented the award to the person in charge of the winning company at the ceremony.

Dr. David Du (first from left) presented the awards to the leaders of the winning companies

The conference brought together influential big shot from government, industry, universities, and medical research. They covered a wide range of topics including innovative therapies focused on clinical applications, neurodegenerative diseases, stem cells, exosomes, gene therapy, RNA technology, oncolytic viruses, and other industries. Experts in their respective fields shared their experiences and results during the conference. Dr. David Du, CEO of Evergreen Therapeutics, former regulatory expert at the FDA Center for Biologics Evaluation and Research (CBER), delivered a keynote speech titled "Requirements and Considerations for Effectiveness Testing of CGT Products." He provided a comprehensive analysis of the regulatory aspects involved in the development process of CGT products. His speech received significant attention and recognition from the audience.

Dr. David Du is giving a keynote speech

After that, Dr. David Du was honored as a guest and joined Professor Liu Hua, Chairman of Shanghai Xinghua Biosciences, Dr. Zhou Li, Chief Scientist of Juventas Cell Therapy Ltd, Dr. Chen Lin, Chief Scientist of Zhongying Biosciences, and Dr. Ye Sen, Chief Application Scientist of Emulate Asia Pacific in a roundtable dialogue on "The manufacturing of cells from the perspective of cost and process" and discussed the theme "The impact of plant construction, cell culture, etc." They exchanged their insights with industry experts.

The roundtable forum is being moderated by Dr. David Du, (positioned first from the left).